Updated Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents Released
The National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA) announce the release of the updated Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.
Selected key updates to the guidelines include the following:
- New information on the diagnosis and management of immune reconstitution inflammatory syndrome (IRIS), particularly as it relates to tuberculosis and cryptococcosis.
- New guidance for managing IRIS related to each opportunistic infection (OI) is provided.
- Updated information on the management of hepatitis B and hepatitis C.
- Immunization strategies for preventing pneumococcal disease and human papillomavirus (HPV) have been updated to reflect the availability of new vaccines and new data.
- Drug interaction information has been updated, particularly as it relates to antiretroviral medications that have been approved since the last update of the guidelines in 2009.
In addition to information on the clinical manifestations, diagnosis, and prevention and treatment of each OI, the guidelines include tables at the end of each chapter and summary tables at the end of the document that list therapeutic options for preventing and treating OIs, adverse drug reactions, pharmacokinetic interactions, dosing recommendations in patients with renal insufficiencies, and therapeutic considerations in pregnancy.
To view or download the guidelines, go to the Adult and Adolescent OI Prevention and Treatment Guidelines section of AIDSinfo. Separate PDF files of the tables can also be downloaded from the page.
Your Feedback Is Welcome
Feedback on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents is welcome. Please send your comments with the subject line “Comments on Adult and Adolescent OI Prevention and Treatment Guidelines” to ContactUs@aidsinfo.nih.gov by May 21, 2013.
FDA Updates Efavirenz Labeling with Expanded Pediatric Indication Information
“On May 2, 2013, the FDA expanded the indication for Sustiva (efavirenz) to include pediatric patients at least three months old and weighing at least 3.5 kg. For pediatric patients who cannot swallow capsules, the capsule contents can be administered with a small amount of food or infant formula using the capsule sprinkle method of administration.
“The updated labeling includes a table for dosing along with the corresponding number of capsules or tablets and strength to administer.”
Other sections of the label that have been updated include the following: Warnings and Precautions, Adverse Reactions, Pediatric Use, Pharmacokinetics, and Clinical Studies.
The updated labeling will be available at the FDA website.
More information is available: